Skeletal muscle-specific expression of human blood coagulation factor IX rescues factor IX deficiency mouse by AAV-mediated gene transfer
- 28 Downloads
- 4 Citations
Abstract
The efficacy of recombinant adeno-associated virus (AAV) vector to deliver and express human blood clotting factor IX (hFIX) gene in skeletal muscle of coagulation factor IX deficiency mouse strain (FactorIX-knockout) is evaluated. The muscle creatine kinase enhancer (MCK) and β-actin promoter (βA) were used to drive the hFIX minigene (hFIXml), which was flanked by AAV inverted terminal repeats (ITRs). Following intramuscular injection of high titer (2.5 × 1011 vector genomes/mL) of rAAV, increased hFIX expression (256 ng/mL of plasma) was achieved. The time course of hFIX expression demonstrated that the expression level gradually increased over a period of two weeks before anti-hFIX antibodies developed in mouse circulating plasma. Those results provided a promising evidence that rAAV-mediated gene transfer and skeletal muscle-specific expression of hFIX is a feasible strategy for treating patients for hemophilia B.
Keywords
AAV hFIX factor IX deficiency mouse direct-muscular gene therapyPreview
Unable to display preview. Download preview PDF.
References
- 1.Yao, S. N., Kurachi, K., Expression of human factor IX in mice after injection of genetically modified myoblasts,Proc. Natl. Acad. Sci. USA, 1992, 89: 3357.PubMedCrossRefGoogle Scholar
- 2.Levy, M. Y., Barron, L. G., Meyer, K. B. et al., Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism expression and secretion of gene products into blood,Gene Therapy, 1996, 3: 201.PubMedGoogle Scholar
- 3.Dwight, D., Kieberl, Ian E., Alexander, A. D. M. et al., Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors,Proc. Natl. Acad. Sci. USA, 1997, 94: 1426.CrossRefGoogle Scholar
- 4.Monahan, P. E., Samulski, R.J., Tazelaar, J. et al., Direct intramuscular injection with rAAV vectors results in sustained expression in a dog model of hemophilia,Gene Therapy, 1998, 5: 40.PubMedCrossRefGoogle Scholar
- 5.Lin, H. F., Maeda, N., Smithies, O. et al., A coagulation factor IX-deficient mouse model for human Hemophilia B,Blood, 1997; 90: 3962.PubMedGoogle Scholar
- 6.Kundu, R. K., Sangiorgi, F., Wu, L. Y. et al., Targeted inactivation of the coagulation factor IX gene cause hemophilia B in mice,Blood, 1998, 92: 168.PubMedGoogle Scholar
- 7.Fan, P. D., Dong, J. Y., Replication of rep-cap genes is essential for the high-efficiency production of recombinant AAV,Human Gene Therapy, 1997, 8: 87.PubMedCrossRefGoogle Scholar
- 8.Wang, J. M., Zheng, H., Kotoku Kurachi et al., Persistent systemic production of human factor IX in mice by skeletal my-oblast-mediated gene transfer: feasibility of repeat application to obtain therapeutic levels,Blood, 1997, 9: 1075.Google Scholar
- 9.Ward, P., Berns, K. I.,In vitro replication of AAV DNA: enhancement by extracts from adenovirus-infected HeLa cells,J. Virol., 1996, 70: 4495.PubMedGoogle Scholar
- 10.Zhou, J. M., Dai, Y. F., Qiu, X. F. et al., Expression of human factor IX cDNA in mice by implants of genetically modi-fied skin fibroblasts from a hemophilia B patient,Science in China, 1993, 36(9): 1082.PubMedGoogle Scholar
- 11.Kung, S. H., Hagstrom, J. N., Cass, D. et al., Human factor IX corrects the bleeding diathesis of mice with hemophilia B,Blood, 1998, 91: 784.PubMedGoogle Scholar
- 12.Fallaux, F. J., Hoeben, R. C., Gene therapy for hemophilias,Curr. Opin. Hematol., 1996, 3: 385.PubMedCrossRefGoogle Scholar
- 13.Rubenstein, R., McVeigh, U., Flotte, T. R. et al., CFTR gene transduction in neonatal rabbits using an AAV vector,Gene Therapy, 1997, 4: 384.PubMedCrossRefGoogle Scholar
- 14.Fisher, K. J., Recombinant adeno-associated virus for muscle directed gene therapy,Nature Med., 1997, 3: 306.PubMedCrossRefGoogle Scholar
- 15.Conrad, C. K., Afione, S. A. et al., Safety of single-dose administration of an AAV-CFTR vector in the primate lung,Gene Therapy, 1996, 3: 658.PubMedGoogle Scholar